Emergent BioSolutions
EBS
$1.98
Share price
-3.88%
Change (1 day)
-83.09%
Change (1 year)
Categories
Emergent BioSolutions (EBS) - Total debt
Total debt on the balance sheet as of December 2023 : $0.86 B
According to Emergent BioSolutions 's latest financial reports the company's total debt is $0.86 B. A company’s total debt is the sum of all current and non-current debts.
Emergent BioSolutions - Total debt on balance sheet (from 2004 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $0.86 B | -38.81% |
| 2022-12-31 | $1.40 B | 67.16% |
| 2021-12-31 | $0.84 B | -3.86% |
| 2020-12-31 | $0.87 B | 7.83% |
| 2019-12-31 | $0.81 B | 2.1% |
| 2018-12-31 | $0.79 B | 5785.93% |
| 2017-12-31 | $13.5 M | -94.96% |
| 2016-12-31 | $0.26 B | 8.59% |
| 2015-12-31 | $0.24 B | -1.64% |
| 2014-12-31 | $0.25 B | 304.84% |
| 2013-12-31 | $62 M | -1.23% |
| 2012-12-31 | $62.77 M | 5.58% |
| 2011-12-31 | $59.45 M | 25.36% |
| 2010-12-31 | $47.42 M | -27.83% |
| 2009-12-31 | $65.71 M | 14.93% |
| 2008-12-31 | $57.18 M | -1.3% |
| 2007-12-31 | $57.93 M | 35.45% |
| 2006-12-31 | $42.77 M | 259.12% |
| 2005-12-31 | $11.91 M | -7.44% |
| 2004-12-31 | $12.86 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $70.84 B | 8,135.88% | 🇺🇸 USA |
 Merck MRK | $35.05 B | 3,975.22% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $22.93 B | 2,566.46% | 🇬🇧 UK |
 Soligenix SNGX | $3.49 M | -99.59% | 🇺🇸 USA |
 SIGA Technologies SIGA | $0.56 M | -99.93% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $2.54 M | -99.70% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $20.15 B | 2,242.83% | 🇮🇱 Israel |